Related Experiment Video
Updated: Jan 9, 2026
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
Exploring the application of PD-1/PD-L1 inhibitors for ovarian cancer
Xinyu Miao1, Zhenpeng Wang1, Dongzhen Liu1
1Department of Gynecologic Oncology, Gynecology and Obstetrics Centre, The First Hospital of Jilin University, Changchun, China.
Abstract:
Ovarian cancer remains one of the leading causes of cancer-related mortality among women worldwide. Although standard treatment regimens, including cytoreductive surgery combined with platinum-based chemotherapy, have achieved certain therapeutic advances, the high recurrence rate and the emergence of platinum resistance continue to represent significant clinical challenges. This highlights the urgent need to explore novel therapeutic strategies.As an emerging modality of immunotherapy, PD-1/PD-L1 inhibitors enhance anti-tumor immune responses by modulating the immune system. Although ovarian cancer has traditionally been regarded as a tumor with low immunogenicity, studies have demonstrated that the presence of tumor-infiltrating lymphocytes and the expression of PD-L1 indicate a potential response to immune checkpoint inhibitors.This review focuses on the application of PD-1/PD-L1 inhibitors in the treatment of ovarian cancer, summarizing their mechanisms of action, clinical research progress, potential combination strategies, and future perspectives. A deeper understanding of the role of immune checkpoint inhibitors in ovarian cancer will contribute to optimizing therapeutic strategies and improving patient outcomes. Despite the potential of PD-1/PD-L1 inhibitors in ovarian cancer treatment, overcoming resistance mechanisms, refining patient selection criteria, and improving safety profiles remain key challenges for clinical application.
Insights
Programmed cell death protein 1 (PD-1)/PD-L1 inhibitors show promise for treating ovarian cancer by enhancing immune responses. Further research is needed to overcome resistance and optimize patient selection for these novel immunotherapies.
Area of Science:
- Oncology
- Immunotherapy
- Cancer Research
Background:
- Ovarian cancer is a leading cause of cancer mortality in women globally.
- Standard treatments like surgery and chemotherapy face challenges due to high recurrence and platinum resistance.
- There is an urgent need for novel therapeutic strategies to improve patient outcomes.
Purpose of the Study:
- To review the application of programmed cell death protein 1 (PD-1)/PD-L1 inhibitors in ovarian cancer treatment.
- To summarize their mechanisms of action, clinical progress, and combination strategies.
- To discuss future perspectives and challenges in utilizing these immunotherapies.
Main Methods:
- Review of existing literature on PD-1/PD-L1 inhibitors in ovarian cancer.
- Analysis of studies demonstrating the role of tumor-infiltrating lymphocytes and PD-L1 expression.
- Exploration of potential combination therapies and resistance mechanisms.
Main Results:
- PD-1/PD-L1 inhibitors enhance anti-tumor immune responses by modulating the immune system.
- Presence of tumor-infiltrating lymphocytes and PD-L1 expression suggest potential response to immune checkpoint inhibitors.
- Clinical research is ongoing, with potential for combination strategies to improve efficacy.
Conclusions:
- PD-1/PD-L1 inhibitors represent a promising immunotherapy for ovarian cancer.
- Optimizing therapeutic strategies requires a deeper understanding of their role and overcoming resistance.
- Key challenges include refining patient selection, improving safety profiles, and addressing resistance mechanisms.
